00

Northeast Pharmaceutical Group Co Ltd

000597 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

4.28CNY-0.10 (-2.28%)

Price History

Full chart

Market Stats

Previous Close4.38
Open4.37
Day Range4.28 – 4.37
52-Week Range4.09 – 5.86
Volume7.31M
Market Cap6.79B
P/E (TTM)31.73
Forward P/E12.30
EPS0.15
Dividend Yield1.17%
Beta0.07
50-Day Avg4.81
200-Day Avg4.97

About

Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. It also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and psychotropic drugs and related products, including morphine hydrochloride injections and tablets, oxycodone hydrochloride injection, compound glycyrrhiza series, and acetaminophen-codeine tablets; anti-AIDS products comprising Krughar /zidovudine tablets and capsules, efavirenz tablets, and other products; and in vitro biological diagnostic reagent products for HIV, HBV, HCV, HPV, and TB. In addition, it offers general health products, including glucosamine sulfate chondroitin collagen D3 calcium capsules, protein powder, probiotic powder, effervescent tablets, chewable tablets, solid drinks, and other products. Further, it provides Enterogermina, magnesium aluminum carbonate chewable tablets; compound proglutamine-cimetidine tablets; acetaminophen tablets; pain relievers, phenacetin, pregabalin, noscapine syrup, and citrate table; and other products, as well as cell therapy products. Additionally, it engages in medical distribution business. The company was founded in 1946 and is based in Shenyang, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yonggang Cai
  • Employees5.73K
  • HeadquartersNo. 8, Kunming Street, Shenyang, China, 110027, China
  • Websitehttps://www.nepharm.com.cn

Leadership

  • Mr. Yonggang CaiGM & Director · b. 1980
  • Ms. Xin LiChief Financial Officer · b. 1980
  • Mr. Li Zhi SongSecretary of the Board · b. 1974
  • Mr. Yan LiuDeputy General Manager · b. 1964
  • Tian XiaAccounting Supervisor

Financials

Income Statement

Currency: CNY1993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.00B934.59M1.05B1.17B757.45M760.62M1.01B1.20B1.44B1.40B1.61B1.62B1.83B2.09B3.71B4.61B5.09B4.83B3.88B3.86B3.87B4.33B3.83B4.81B5.68B7.47B8.22B7.38B8.15B8.81B8.24B7.50B7.07B
Growth (%)--6.71%+12.32%+11.08%-35.04%+0.42%+32.99%+18.39%+20.41%-3.12%+15.02%+0.80%+13.17%+14.23%+76.99%+24.38%+10.50%-5.20%-19.59%-0.46%+0.15%+11.96%-11.51%+25.56%+17.90%+31.54%+10.09%-10.17%+10.30%+8.15%-6.42%-8.98%-5.70%
Cost of Revenue727.06M716.58M891.21M1.02B608.21M560.43M734.71M897.56M1.13B1.11B1.23B1.24B1.41B1.50B2.98B3.03B3.54B3.70B3.09B2.95B2.73B3.05B2.93B3.39B3.51B4.47B4.77B4.60B5.06B5.56B5.12B4.74B4.44B
Gross Profit274.79M218.01M158.52M147.90M149.24M200.19M276.83M300.00M310.23M285.47M379.68M375.96M422.47M443.87M722.40M1.58B1.56B1.13B792.61M913.90M1.15B1.29B908.73M1.42B2.17B3.00B3.45B2.79B3.09B3.25B3.12B2.76B2.64B
Gross Margin27.43%23.33%15.10%12.68%19.70%26.32%27.37%25.05%21.51%20.43%23.63%23.21%23.05%21.20%19.49%34.24%30.58%23.42%20.41%23.65%29.59%29.72%23.70%29.53%38.18%40.12%41.97%37.76%37.93%36.92%37.83%36.81%37.27%
Operating Expense227.30M145.65M109.11M122.35M136.23M122.32M227.93M262.27M284.67M271.05M371.32M308.20M374.56M392.18M452.83M1.08B1.03B962.00M1.16B1.11B1.35B1.28B1.31B1.42B2.05B2.92B3.24B2.64B2.90B2.56B2.62B2.18B2.14B
Operating Income47.49M72.36M49.41M25.55M13.01M77.86M48.90M37.74M25.55M14.42M8.37M67.75M47.92M51.69M269.57M494.95M532.40M168.90M-365.26M-196.02M-202.88M7.15M-403.17M1.60M114.53M75.96M209.96M153.15M187.35M696.36M498.23M577.76M498.81M
Operating Margin4.74%7.74%4.71%2.19%1.72%10.24%4.83%3.15%1.77%1.03%0.52%4.18%2.61%2.47%7.27%10.74%10.45%3.50%-9.41%-5.07%-5.24%0.16%-10.51%0.03%2.02%1.02%2.55%2.07%2.30%7.91%6.04%7.70%7.05%
EBITDA93.58M109.75M64.72M32.05M56.14M128.16M131.91M129.47M140.23M134.28M135.32M136.83M161.98M170.85M303.76M716.07M809.72M389.62M-53.41M-37.07M103.81M332.10M-50.26M440.10M656.34M497.74M630.50M694.29M722.45M754.38M911.39M1.02B896.50M
EBITDA Margin9.34%11.74%6.16%2.75%7.41%16.85%13.04%10.81%9.72%9.61%8.42%8.45%8.84%8.16%8.20%15.53%15.90%8.07%-1.38%-0.96%2.68%7.66%-1.31%9.14%11.56%6.67%7.67%9.40%8.87%8.56%11.06%13.58%12.67%
Net Income44.01M63.22M47.10M19.95M-69.24M35.52M43.38M19.47M3.83M9.67M8.68M5.99M12.42M24.58M47.52M357.91M476.08M53.44M-394.28M8.10M-166.96M87.08M-384.36M23.79M119.00M195.20M173.98M12.26M99.03M350.25M358.46M409.85M260.07M
Net Income Margin4.39%6.76%4.49%1.71%-9.14%4.67%4.29%1.63%0.27%0.69%0.54%0.37%0.68%1.17%1.28%7.76%9.35%1.11%-10.15%0.21%-4.31%2.01%-10.02%0.49%2.10%2.61%2.12%0.17%1.22%3.98%4.35%5.46%3.68%
R&D--------------------15.60M84.34M26.26M30.90M57.66M144.67M63.94M74.18M83.46M160.39M194.08M236.26M172.27M
R&D as % of Total Revenue--------------------0.40%1.95%0.68%0.64%1.02%1.94%0.78%1.00%1.02%1.82%2.35%3.15%2.43%
Interest Expense45.84M47.28M26.93M13.88M65.48M70.43M72.94M65.98M78.81M77.32M64.65M47.12M40.27M39.42M70.10M111.11M97.30M118.91M114.38M141.59M162.61M171.78M157.26M166.66M164.41M173.49M137.20M146.84M164.70M130.47M133.22M112.47M49.16M
Interest Expense % of Total Revenue4.58%5.06%2.57%1.19%8.65%9.26%7.21%5.51%5.47%5.53%4.02%2.91%2.20%1.88%1.89%2.41%1.91%2.46%2.95%3.66%4.20%3.96%4.10%3.46%2.90%2.32%1.67%1.99%2.02%1.48%1.62%1.50%0.69%

Balance Sheet

Currency: CNY1993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.50B1.60B2.45B3.10B2.17B2.59B2.60B2.67B2.76B2.68B2.52B2.43B2.30B2.21B3.05B4.10B6.08B5.61B5.87B5.99B7.55B8.57B8.69B9.79B10.59B11.72B12.54B12.17B13.18B13.81B15.27B14.45B12.89B
Total Liabilities1.05B1.11B1.68B2.10B1.23B1.59B1.73B1.76B1.87B1.81B1.65B1.55B1.40B1.28B2.16B2.53B4.03B3.54B4.13B4.24B5.96B5.81B6.29B7.36B8.05B8.13B8.62B8.04B8.89B9.10B10.11B8.88B7.22B
Total Equity451.06M487.14M775.11M994.58M935.36M824.17M869.55M872.01M861.54M873.25M870.26M884.02M900.07M927.49M887.38M1.57B2.02B2.02B1.66B1.67B1.50B2.66B2.29B2.31B2.43B3.47B3.81B3.98B4.14B4.56B4.99B5.32B5.53B
Cash24.99M118.60M130.17M130.93M85.19M86.89M161.26M213.94M220.79M336.53M359.61M464.34M371.13M213.99M319.38M768.00M1.76B1.06B798.06M852.32M1.54B1.77B1.71B1.77B1.71B1.28B1.53B1.48B2.55B3.84B5.65B4.47B3.60B
Total Debt684.60M727.10M1.27B1.56B867.10M951.26M1.08B872.61M967.52M1.09B777.58M794.13M619.17M606.84M1.38B1.57B2.63B2.12B2.07B2.90B3.21B3.42B3.78B4.11B3.82B3.05B3.02B3.51B3.40B2.14B2.18B1.57B-
Net Debt659.61M608.51M1.14B1.43B781.91M864.37M914.61M862.56M912.52M753.89M510.66M329.79M297.92M392.84M1.11B801.37M863.12M1.17B1.84B2.04B1.67B1.33B2.08B1.64B2.11B1.76B2.41B2.03B847.35M-1.61B1.26B-2.90B-

Cash Flow

Currency: CNY1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.59M54.62M36.13M78.84M157.41M230.08M211.06M111.40M-106.00M198.56M709.03M615.91M255.96M-233.32M86.09M-266.38M46.99M99.70M384.51M-301.20M285.09M352.60M570.92M746.51M1.11B586.75M758.76M1.11B
Investing Cash Flow33.16M-23.87M44.86M-38.63M-15.73M-77.59M-79.49M-65.98M-39.47M-65.47M-315.31M-519.84M-332.41M-292.54M-174.31M-450.64M-472.90M-383.73M-535.03M-51.70M-563.02M-232.07M-322.67M-100.07M-256.34M-227.96M-283.97M-
Financing Cash Flow-23.86M43.58M-25.31M-13.61M-25.94M-129.41M-26.84M-132.63M-11.67M-33.02M-142.71M892.00M-548.01M292.96M85.73M1.43B656.73M171.13M91.10M117.77M-145.23M-104.92M-359.28M-132.39M-58.99M381.10M-1.15B-
Capital Expenditure21.44M9.41M12.18M46.57M38.07M87.46M61.14M103.66M47.84M87.78M359.27M862.78M473.93M421.65M178.90M452.02M532.27M346.04M177.01M414.63M565.74M229.17M400.38M119.81M244.13M235.43M159.43M97.78M
Free Cash Flow-29.03M45.22M23.94M32.27M119.34M142.63M149.92M7.75M-153.84M110.78M349.76M-246.88M-217.97M-654.97M-92.81M-718.41M-485.28M-246.34M207.51M-715.83M-280.65M123.43M170.54M626.70M864.44M351.32M599.34M1.01B
Dividends Paid78.32M82.83M62.33M66.59M64.71M66.47M54.03M25.94M17.23M67.90M129.01M123.10M163.56M142.02M175.43M189.92M199.64M184.23M156.43M159.28M166.56M135.59M124.96M10.78M18.87M219.78M206.14M196.90M
FCF to OCF382.29%82.78%66.27%40.93%75.81%61.99%71.03%6.95%145.13%55.79%49.33%-40.08%-85.16%280.72%-107.81%269.69%-1032.71%-247.08%53.97%237.66%-98.44%35.01%29.87%83.95%77.98%59.88%78.99%91.16%
Dividend Paid to FCF-269.77%183.19%260.34%206.35%54.23%46.60%36.04%334.87%-11.20%61.29%36.89%-49.86%-75.04%-21.68%-189.01%-26.44%-41.14%-74.78%75.39%-22.25%-59.35%109.85%73.27%1.72%2.18%62.56%34.39%19.52%

Earnings

Report DateOct 28, 2009Mar 9, 2010Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Feb 27, 2013May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 28, 2014Aug 26, 2014Oct 29, 2014Feb 25, 2015Apr 28, 2015Aug 28, 2015Oct 29, 2015Mar 21, 2016Apr 26, 2016Aug 30, 2016Oct 26, 2016Mar 1, 2017Apr 26, 2017Aug 28, 2017Oct 29, 2017Apr 27, 2018Aug 29, 2018Oct 29, 2018Apr 2, 2019Aug 27, 2019Oct 30, 2019Apr 29, 2020Aug 28, 2020Oct 27, 2020Mar 17, 2021Apr 28, 2021Aug 27, 2021Oct 28, 2021Mar 18, 2022Apr 28, 2022Aug 29, 2022Oct 29, 2022Mar 30, 2023Apr 28, 2023Aug 23, 2023Oct 27, 2023Mar 30, 2024May 14, 2024Aug 28, 2024Oct 24, 2024Mar 13, 2025Apr 18, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate0.150.16---------------------------------------------------------------
EPS Actual0.16-0.010.150.080.01-0.170.01-0.01-0.18-0.35-0.10-0.060.29-0.11-0.04-0.01-0.07-0.120.090.04-0.040.03-0.07-0.12-0.29-0.34-0.010.020.010.020.020.060.080.110.110.070.090.050.04-0.000.06-0.040.010.030.02-0.030.050.050.030.010.160.050.050.060.100.040.070.040.140.030.070.030.060.020.04
Surprise6.67%-106.25%---------------------------------------------------------------
TimingPre-marketPre-market-----------------Pre-marketPre-market-Pre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-market---------Pre-marketPre-market-------After-hours---After-hours-----

Key Statistics & Ratios

Market Cap6.79B
Enterprise Value4.53B
Trailing P/E31.73
Forward P/E12.30
PEG Ratio0.00
Price / Sales1.04
Price / Book1.23
EPS0.15
Book Value3.88
Revenue (TTM)6.56B
Gross Profit (TTM)2.20B
EBITDA633.48M
Profit Margin3.28%
Operating Margin-0.39%
Return on Equity2.81%
Return on Assets0.75%
Shares Outstanding1.43B
Shares Float579.50M
Beta0.07
Dividend Yield1.17%
Dividend Rate0.06
Payout Ratio36.45%

Dividends

20261×
0.06Jun 23, 2026
20251×
0.10Jun 23, 2025
20241×
0.10May 23, 2024
20231×
0.10May 16, 2023
20221×
0.01May 27, 2022
20211×
0.01May 27, 2021
20101×
0.05Apr 30, 2010
20091×
0.05Jun 29, 2009
20081×
0.03Apr 21, 2008

Stock Splits

  • May 20, 20201.49:1
  • Sep 24, 20191.49:1
  • Feb 14, 200613.6:10
  • Jul 29, 19991.2:1
  • Jul 10, 19981.3:1